ライフサイエンスコーパス: MRSA

1 MRSA emerged in the mid-1940s, following the acquisition

2 MRSA hand carriage rates in patients, nurses, and dentis

3 MRSA is particularly difficult to treat when it invades

4 MRSA isolates underwent whole-genome sequencing, with a

5 MRSA prevalence decreased by a relative 3.2% countywide,

6 MRSA prevalence was significantly higher in intermediate

7 MRSA strains have acquired a non-native penicillin-bindi

8 MRSA strains lacking STK1 become susceptible to failing

9 MRSA transmission dynamics between the ACH and ILTCFs we

10 At least 1 MRSA isolate from each individual underwent whole-genome

11 We identified 15 MRSA-positive individuals with 27 highly related MRSA is

12 24 MRSA isolates (70.6%) were multi-resistant and 18 (52.9%

13 ccessed whole genome sequence data for 2,283 MRSA isolates from 1,465 people identified during a 12-m

14 arming genetic relatedness between 7 (20.6%) MRSA isolates and the epidemic EMRSA-15 clone, as well a

15 ment to accelerate ulcer healing and address MRSA into the care of diabetic patients with foot ulcers

16 Although vancomycin is active against MRSA, it does not effectively kill intracellular MRSA du

17 rate potent antibacterial activities against MRSA, MRSE and VRE (MIC = 0.003-0.78 microM).

18 inhibition), antibacterial activity against MRSA and MSSA and cytotoxicity against NCI-H460, MCF-7 a

19 extracellular bactericidal activity against MRSA at concentrations equal to and four-fold less than

20 hows specific antibacterial activity against MRSA by a membrane-disruptive mechanism without detectab

21 ew and effective antimicrobial agent against MRSA infection.

22 olecular synthesis inhibition assays against MRSA.

23 designed, synthesized and evaluated against MRSA and menaquinone utilizing bacteria in aerobic condi

24 nt (>/=99.9% persister cell killing) against MRSA (MBEC < 10 muM), MRSE (MBEC = 2.35 muM), and VRE (M

25 activities (MBEC = 0.59-9.38 microM) against MRSA, MRSE and VRE biofilms while showing minimal red bl

26 ivities with MICs ranging 1-8 mug/mL against MRSA strains.

27 nted for 16% (7/44) and 21% (211/985) of all MRSA BSIs and SSTIs, corresponding to 1.2 and 37.4 cases

28 which prompted retrospective analysis of all MRSA isolates obtained from the environment (n = 62), SS

29 Among MRSA-negative and -unknown cardiac surgery patients, SSI

30 resent the mechanistic range shift analysis (MRSA), a method to estimate a suite of range shift param

31 isolated from 527 participants (67.0%), and MRSA was isolated from 388 (49.4%).

32 dominant bacteria species was S. aureus and MRSA infection is increasingly prevalent.

33 equilibrium and decrease PGN, S. aureus and MRSA-triggered inflammatory response.

34 ompetition experiments between S. caprae and MRSA demonstrated a significant reduction in MRSA burden

35 ensus tract-level socioeconomic measures and MRSA incidence, which may include modifiable social (eg,

36 lms formed by a variety of clinical MSSA and MRSA strains and created culture-negative implants in th

37 le with the objective of enhancing both anti-MRSA activity and drug-like properties.

38 lenge of accurately targeting empirical anti-MRSA antibiotics with currently available clinical tools

39 It also potentiated the anti-MRSA activity of oxacillin in a synergistic fashion, res

40 t the evolutionary history of the archetypal MRSA.

41 lance data for invasive community-associated MRSA cases (isolated from a normally sterile site of an

42 Annual invasive community-associated MRSA incidence was 4.59 per 100000 among whites and 7.60

43 l disparity in invasive community-associated MRSA rates was largely explained by socioeconomic factor

44 g racial disparities in community-associated MRSA rates.

45 tion of black race with community-associated MRSA remained (RR, 1.05; 95% CI, .92-1.20).

46 l isolates (methicillin-resistant S. aureus (MRSA) and Candida albicans) and standard (Pseudomonas ae

47 SSA) and HO methicillin-resistant S. aureus (MRSA) BSIs for 2009-2013 at 2 hospitals and used an adju

48 pansion for methicillin-resistant S. aureus (MRSA) in cases of cellulitis associated with specific ri

49 aureus) and methicillin-resistant S. aureus (MRSA) induced peritonitis.

50 d to reduce methicillin-resistant S. aureus (MRSA) or methicillin-susceptible S. aureus (MSSA) burden

51 mmon USA300 methicillin-resistant S. aureus (MRSA) strains express a number of toxins, such as Panton

52 , including methicillin-resistant S. aureus (MRSA) strains, despite high titers of specific antibodie

53 S. aureus, methicillin-resistant S. aureus (MRSA), multidrug-resistant S. aureus (MDRSA), absence of

54 C-harboring methicillin-resistant S. aureus (MRSA), which failed to identify from 0 to 41% of tested

55 S.aureus and Methicillin-resistant S.aureus (MRSA) are mediated via the secretion of soluble factors

56 methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Acinetobacter baumannii (M

57 methicillin-resistant staphylococcus aureus (MRSA) and self-assembles to form nanoaggregates on the s

58 methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) due to

59 methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE).

60 methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE

61 methicillin resistant Staphylococcus aureus (MRSA) and vancomycin-resistant strains.

62 methicillin-resistant Staphylococcus aureus (MRSA) carriage in dental clinics.

63 Methicillin-resistant Staphylococcus aureus (MRSA) caused 57% of the ISIs.

64 methicillin-resistant Staphylococcus aureus (MRSA) growth.

65 methicillin-resistant Staphylococcus aureus (MRSA) has declined over the past decade, but it is uncle

66 Methicillin Resistant Staphylococcus aureus (MRSA) have been reported to survive on hospital surfaces

67 methicillin-resistant Staphylococcus aureus (MRSA) identified through routine practice.

68 methicillin-resistant Staphylococcus aureus (MRSA) incidence in the United States is higher among bla

69 Methicillin-resistant Staphylococcus aureus (MRSA) infection is a global health care problem.

70 Methicillin-resistant Staphylococcus aureus (MRSA) infection is a serious threat to the public health

71 methicillin-resistant Staphylococcus aureus (MRSA) infection was 24% and multidrug resistance (MDR) w

72 methicillin-resistant Staphylococcus aureus (MRSA) infection.

73 methicillin-resistant Staphylococcus aureus (MRSA) infection.

74 methicillin-resistant Staphylococcus aureus (MRSA) infections are a burden on the health care system.

75 Methicillin-resistant Staphylococcus aureus (MRSA) infections are a global public health problem.

76 methicillin-resistant Staphylococcus aureus (MRSA) infections between 2010 and 2014 primarily reflect

77 methicillin-resistant Staphylococcus aureus (MRSA) infections by demonstrating that oxacillin can be

78 Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium that causes infections in different

79 Methicillin-resistant Staphylococcus aureus (MRSA) is an emerging cause of catheter-associated urinar

80 Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for large numbers of postsurgical n

81 Methicillin-resistant Staphylococcus aureus (MRSA) is the most common healthcare-associated multidrug

82 methicillin-resistant Staphylococcus aureus (MRSA) is unclear.

83 methicillin-resistant Staphylococcus aureus (MRSA) isolates.

84 methicillin-resistant Staphylococcus aureus (MRSA) over sensitive isolates (methicillin-sensitive S.

85 Methicillin-resistant Staphylococcus aureus (MRSA) phenotypes were predicted using PPFS2 and compared

86 methicillin-resistant Staphylococcus aureus (MRSA) plates by recognition of pigmented colonies.

87 methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health.

88 Methicillin-resistant Staphylococcus aureus (MRSA) represents a major contributor to this trend.

89 methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infection (SSTI).

90 methicillin-resistant Staphylococcus aureus (MRSA) status, and receipt of mupirocin.

91 methicillin-resistant Staphylococcus aureus (MRSA) via regulation of principal virulence factors (eg,

92 Methicillin-resistant Staphylococcus aureus (MRSA) was first observed in 1960, less than one year aft

93 Meticillin-resistant Staphylococcus aureus (MRSA) was first reported in 1998 at 7.7% and represented

94 methicillin-resistant Staphylococcus aureus (MRSA)(1,2).

95 methicillin-resistant Staphylococcus aureus (MRSA), Listeria monocytogenes and Enterococcus faecalis,

96 methicillin-resistant Staphylococcus aureus (MRSA).

97 methicillin-resistant Staphylococcus aureus (MRSA).

98 methicillin-resistant Staphylococcus aureus (MRSA).

99 methicillin-resistant Staphylococcus aureus (MRSA).

100 methicillin-resistant Staphylococcus aureus (MRSA).

101 methicillin-resistant Staphylococcus aureus (MRSA).

102 e methicillin-resistantStaphylococcus aureus(MRSA) infections.

103 vidence of a higher prevalence of S. aureus, MRSA, and MDRSA among children living with an IHO worker

104 ethicillin-resistant Sthaphylococcus aureus, MRSA and Pseudomonas aeruginosa, P. aeruginosa) were ana

105 categorized 100% and 61.3% of isolates to be MRSA, respectively.

106 cantly increases the severity of bloodstream MRSA infection, even when administered in conjunction wi

107 a diverse range of S. aureus, including both MRSA and MSSA.

108 Complete growth inhibition of both MRSA strains was demonstrated (1) for both rose bengal c

109 % confidence interval (CI): 1.07, 1.83], but MRSA nasal carriage prevalence was uncommon (2-3%) in IH

110 mpounds also inhibited the biofilm growth by MRSA at high concentration.

111 s, the difference in risk-benefit profile by MRSA status suggests that MRSA-screening-directed prophy

112 CA-MRSA exhibited increased cell-wall-associated WTA conten

113 hicillin-resistant Staphylococcus aureus (CA-MRSA) are the cause of a severe pandemic consisting prim

114 hicillin-resistant Staphylococcus aureus (CA-MRSA) causes infections associated with extensive tissue

115 hicillin-resistant Staphylococcus aureus (CA-MRSA) epidemic in the United States is largely attributa

116 hicillin-resistant Staphylococcus aureus (CA-MRSA) with specific molecular characteristics.

117 thicillin-resistant Staphylococcus aureus(CA-MRSA) isolates have revealed a wide diversity of genetic

118 culminate in lysis of neutrophils during CA-MRSA infection may serve as a novel therapeutic interven

119 1 inhibits lysis of human neutrophils fed CA-MRSA and attributed the process to necroptosis.

120 Human neutrophils fed CA-MRSA lacked phosphorylated RIPK-1, as well as phosphoryl

121 In vitro, human neutrophils fed CA-MRSA lyse by an unknown mechanism that is inhibited by n

122 Neutrophils fed CA-MRSA possessed cytoplasmic complexes that included inact

123 test the hypothesis that neutrophils fed CA-MRSA undergo necroptosis.

124 , these data suggest that neutrophils fed CA-MRSA underwent a novel form of lytic programmed cell dea

125 Lysis of neutrophils fed CA-MRSA was independent of tumor necrosis factor alpha, act

126 defines virulence particularly of global CA-MRSA lineages is poorly understood.

127 estors, including USA500 and a "historic" CA-MRSA from Western Australia, were shown to be only dista

128 trol programmes targeting transmission of CA-MRSA will be required to control MRSA in both the commun

129 ortant role for the elevated virulence of CA-MRSA.

130 , containment, and possible extinction of CA-MRSA.

131 solates were able to grow on all chromogenic MRSA screening plates tested.

132 Within common MRSA clonal complexes, 3/14 MSSA and 2/21 PSSA isolates

133 The overall prevalence of confirmed MRSA pneumonia was 3.0% (n=95), with differing prevalenc

134 ssion of CA-MRSA will be required to control MRSA in both the community and hospital.

135 caused by drug-resistant strains, designated MRSA (methicillin-resistant S. aureus), is associated wi

136 to infer the time point at which this early MRSA lineage arose and when SCCmec was acquired.

137 nization vs Universal Clearance to Eradicate MRSA]) showed that body surface decolonisation reduced a

138 f Fg in the urinary tract, which facilitated MRSA colonization.

139 genome sequencing a collection of the first MRSA isolates allows us to reconstruct the evolutionary

140 d 97.6% specific (95% CI, 96.2 to 98.5%) for MRSA detection across six testing sites.

141 sults show that screening all admissions for MRSA is unlikely to be cost effective in England at the

142 e, chlorhexidine bathing, decolonization for MRSA, and hydrogen peroxide vaporizer for MDR-AB) were u

143 naked eye for all tested isolates except for MRSA.

144 fundamental infection control practices for MRSA and MDR-AB (ie, contact precautions, private room/c

145 STK1, despite being nonessential protein for MRSA survival, it can serve as an important therapeutic

146 e reference method, the positivity rates for MRSA in the population evaluated were 11.1% (122/1,103)

147 vealed that catheterization was required for MRSA to achieve high-level, persistent infection in the

148 s classes suggests a long-term reservoir for MRSA in this setting.

149 A total of 1700 inpatients were screened for MRSA over a 6-week period in 2014.

150 of a dental clinic in Egypt were tested for MRSA.

151 egies for "step-down" antibiotic therapy for MRSA-BSI; (4) management of staphylococcal BSIs in neona

152 ges and neutrophils, and protected mice from MRSA infection in two model systems.

153 Although fundamental MRSA and MDR-AB control practices are used regularly in

154 Furthermore, MRSA exacerbated the host inflammatory response to stimu

155 us) and antibiotic-resistant bacteria (e.g., MRSA).

156 no evidence of community transmission of HA-MRSA strains, implying that HA-MRSA cases identified in

157 mission of HA-MRSA strains, implying that HA-MRSA cases identified in the community originate from th

158 rying numbers, misidentifying mecC-harboring MRSA as methicillin-susceptible S. aureus This study und

159 All mecC-harboring MRSA isolates were able to grow on all chromogenic MRSA

160 ntify from 0 to 41% of tested mecC-harboring MRSA isolates.

161 However, mecC-harboring MRSA strains pose special difficulties in their detectio

162 ability to correctly identify mecC-harboring MRSA, including three (semi)automated antimicrobial susc

163 y to address the challenge of mecC-harboring MRSA.

164 bility to reliably screen for mecC-harboring MRSA.

165 Results suggest high MRSA pathogenicity in dental wards highlighting the need

166 nicity were significantly associated with HO-MRSA BSIs whereas Hispanic ethnicity was negatively asso

167 an race was significantly associated with HO-MRSA but not MSSA BSIs.

168 In MRSA infection mouse model, MCL down-regulated the expre

169 In MRSA-colonized patients undergoing cardiac surgery, SSI

170 lpha (TNF-alpha) and interleukin-6 (IL-6) in MRSA-infected skin lesions.

171 5.6%), attributable to an annual decline in MRSA of 10.9% (9.3% to 12.6%).

172 level factors associated with differences in MRSA incidence and inverse odds ratio-weighted mediation

173 t of vancomycin dosing on patient outcome in MRSA bloodstream infection (BSI); (2) defining, testing,

174 MRSA demonstrated a significant reduction in MRSA burden using murine models of both skin colonizatio

175 tion bundle experienced a 17.4% reduction in MRSA rates (P = .03).

176 e number needed to treat to prevent 1 SSI in MRSA-colonized patients is estimated to be 53, compared

177 d with postdischarge MRSA infection included MRSA colonization (matched odds ratio [mOR], 7.71; 95% c

178 netic clusters were suggestive of interclass MRSA transmission.

179 y than free vancomycin against intracellular MRSA and other intracellular pathogens.

180 , it does not effectively kill intracellular MRSA due to the molecular size and polarity that limit i

181 ancomycin for the treatment of intracellular MRSA infection.

182 the macrophages infected with intracellular MRSA bacteria, the RBC-nanogels significantly inhibited

183 Using a murine model of intradermal MRSA infection, the therapeutic efficacy of synthetic S.

184 ices that are effective at limiting invasive MRSA infections.

185 Hospitalizations related to invasive MRSA remained largely unchanged.

186 LA-MRSA CC398 caused 24.3 BSIs per 1000 SSTIs among people

187 LA-MRSA has been isolated previously from animals and human

188 Staphylococcus aureus clonal complex 398 (LA-MRSA CC398) is causing an increasing number of skin and

189 ssess the phylogenetic relationship among LA-MRSA CC398 isolates from Danish pigs and cases of BSI an

190 hicillin-resistant Staphylococcus aureus (LA-MRSA) is an emerging problem in many parts of the world.

191 types of MRSA and cases of SSTI caused by LA-MRSA CC398.

192 inical epidemiology of all human cases of LA-MRSA CC398 BSI during 2010-2015.

193 Cases of LA-MRSA CC398 BSI were compared to cases of BSI caused by o

194 The number of LA-MRSA CC398 BSIs and SSTIs increased over the years, peak

195 emonstrates that the increasing number of LA-MRSA CC398 BSIs occurred in parallel with a much larger

196 ed in parallel with a much larger wave of LA-MRSA CC398 SSTIs and an expanding pig reservoir.

197 Our data demonstrate a low burden of LA-MRSA in the East of England, but the detection of mecC-M

198 to describe the molecular epidemiology of LA-MRSA isolated in the East of England (broadly Cambridge

199 We identified 13 putative LA-MRSA isolates from 12 individuals, giving an estimated p

200 sed over the years, peaking in 2014, when LA-MRSA CC398 accounted for 16% (7/44) and 21% (211/985) of

201 Most patients with LA-MRSA CC398 BSI had no contact to livestock, although the

202 ulence factors previously associated with LA-MRSA.

203 ed outcomes compared with treatments lacking MRSA activity.

204 rotection studies in mice against the lethal MRSA challenge indicated that at high concentration neit

205 e East of England, but the detection of mecC-MRSA and ST398 indicates the need for vigilance.

206 Twelve isolates were mecC-MRSA (ten CC130, one ST425 and one ST1943) and single is

207 hat the RBC-nanogels effectively neutralized MRSA-associated toxins in extracellular environment and

208 s estimated to be 53, compared to 176 in non-MRSA patients.

209 ming isolates represented 23.5% and 29.4% of MRSA isolates.

210 eutic strategies to address the challenge of MRSA infection.

211 describe the transmission characteristics of MRSA in hospital setting.

212 A cluster of MRSA SSIs occurred in early 2016 with the isolates confi

213 Given the contribution of MRSA agr type I isolates to human disease, vaccine targe

214 d specific assay for the direct detection of MRSA from nasal swab specimens.

215 ed FDA clearance for the direct detection of MRSA from nasal swabs.

216 e need for greater focus on the detection of MRSA outbreaks and transmission in the community.

217 The primary outcome was the duration of MRSA bacteremia in days.

218 ities (ILTCFs), the transmission dynamics of MRSA between healthcare settings is not well understood.

219 ram-negative pathogens, and the emergence of MRSA, highlight the growing challenge of bloodstream inf

220 original driving factor in the evolution of MRSA as previously thought.

221 e genes and disrupt the biofilm formation of MRSA clearly indicated that Inh2-B1 serves as a therapeu

222 However, the growth of MRSA was inhibited, and a significant protection in mice

223 this burden, as the timely identification of MRSA colonization or infection facilitates infection con

224 s encompassing in vitro growth inhibition of MRSA, and in vivo protection studies in mice against the

225 nce study revealed multiple introductions of MRSA CC398 in a UK Equine Hospital, identifying an emerg

226 e surveillance and outbreak investigation of MRSA in the United Kingdom and Ireland and have shown th

227 occus aureus (including clinical isolates of MRSA and MSSA) and Staphylococcus epidermidis identified

228 increased susceptibility to host killing of MRSA.

229 auranofin is efficacious in a mouse model of MRSA systemic infection and significantly reduces the ba

230 The clinical presentation of MRSA CAP overlapped substantially with pneumococcal CAP,

231 The high prevalence of MRSA and MDR bacterial pathogens dictate the need for ef

232 United Kingdom shows that the proportion of MRSA bacteremias apportioned to hospitals is decreasing,

233 This study identified preventable routes of MRSA CC398 introduction and transmission: human occupati

234 small molecules that restore sensitivity of MRSA to beta-lactams.

235 detect and track the emergence and spread of MRSA clones of human importance.

236 ing skin challenge with a virulent strain of MRSA.

237 les to form nanoaggregates on the surface of MRSA.

238 vealed intra- and interclass transmission of MRSA among military trainees.

239 o current clinical practice for treatment of MRSA infection, with the potential to significantly impr

240 s of patient outcomes for clinical trials of MRSA-BSI; (3) testing new strategies for "step-down" ant

241 red to cases of BSI caused by other types of MRSA and cases of SSTI caused by LA-MRSA CC398.

242 lar to the ratio observed for other types of MRSA.

243 encing (WGS) can refine our understanding of MRSA transmission and microevolution in congregate setti

244 to significantly attenuate the virulence of MRSA despite the pathogen being resistant to this drug.

245 WGS of MRSA isolates sent to a regional microbiological laborat

246 eived as a vertical intervention focusing on MRSA, it also expanded infection prevention and control

247 Yet, its impact on MRSA bloodstream infections (BSIs) has not been well stu

248 delineate the impact of propofol sedation on MRSA bloodstream infections in mice in the presence and

249 Overall, MRSA was identified in 62/540 (11.5%) of environmental s

250 riaxone/Cefotaxime against highly pathogenic MRSA infection.

251 Among 34 mecA-positive MRSA isolates, five (14.7%) were PVL-positive, seventeen

252 and susceptibility testing of mecC-positive MRSA isolates.

253 atus as the superior surrogate mecC-positive MRSA marker.

254 independently associated with postdischarge MRSA infection included MRSA colonization (matched odds

255 The predicted MRSA phenotype was accurate in all but three isolates.

256 decolonization without screening to prevent MRSA infection in intensive-care unit (ICU) patients.

257 tly associated with MRSA pneumonia: previous MRSA infection or colonisation (odds ratio 6.21, 95% CI

258 long-term care facilities, those with prior MRSA exposure, and intravenous drug users.

259 ers the urinary tract environment to promote MRSA CAUTI pathogenesis by inducing the release of Fg, w

260 s to the localized host defense in recurrent MRSA SSSI.

261 Furthermore, among cases of recurrent MRSA SSTI, we evaluated the intrahost relatedness of inf

262 among isolates from patients with recurrent MRSA infections.

263 Among trainees with recurrent MRSA SSTI, the intrahost median SNV difference was 7.5 (

264 he protective host defense against recurring MRSA infection.

265 In 2013, a cluster-randomised trial (REDUCE MRSA Trial [Randomized Evaluation of Decolonization vs U

266 REDUCE-MRSA was a 3-arm, cluster-randomized trial of either scr

267 -positive individuals with 27 highly related MRSA isolates who were linked to the GP surgery, 2 of wh

268 Menaquinone (MK-4) supplementation rescued MRSA growth, suggesting these compounds inhibit MK biosy

269 of the problematic fluoroquinolone-resistant MRSA, VRE, and S. pneumoniae, and the possibility to off

270 tal types (acute, teaching, and specialist), MRSA prevalence, and transmission potentials using proba

271 This long-term MRSA surveillance study revealed multiple introductions

272 Following infection, we showed that MRSA attached to the urothelium and implant in patterns

273 benefit profile by MRSA status suggests that MRSA-screening-directed prophylaxis may optimize benefit

274 The MRSA also revealed a trade-off between the probability o

275 We applied the MRSA to a population of GPS tracked roe deer (Capreolus

276 ificant increased fluorescence signal at the MRSA infected site.

277 F-Van shows strong radioactive signal in the MRSA-infected lungs in a murine model.

278 Using the MRSA, we were able to quantify the behaviours across the

279 Facilities with >/=75% compliance with the MRSA prevention bundle experienced a 17.4% reduction in

280 A and ClfB) have been shown to contribute to MRSA-Fg interactions in other models of disease.

281 increases an individual's susceptibility to MRSA UTI.

282 a and sepsis, we show that oxacillin-treated MRSA strains are significantly attenuated in virulence.

283 spp. and Staphylococcus spp., including two MRSA strains 0.3-8 mug/mL) than for the majority of Gram

284 WGS was performed on colonizing USA300 MRSA isolates from 74 individuals within 72 hours of adm

285 placement with a genetically distinct USA300 MRSA population.

286 Eighty USA300 MRSA clinical isolates from 74 trainees, 6 (8.1%) of who

287 e training classes with >/=5 cases of USA300 MRSA SSTI were selected.

288 We identified clusters of USA300 MRSA SSTI within select training classes and performed W

289 Recurrent infections with USA300 MRSA are common, yet intrahost evolution during persiste

290 f antimicrobial regimens possessing in vitro MRSA activity provide improved outcomes compared with tr

291 1.3% of the environmental isolates were MRSA-positive.

292 k factors were independently associated with MRSA pneumonia: previous MRSA infection or colonisation

293 inked to the GP surgery, 2 of whom died with MRSA bacteremia.

294 s and kidney pathology in mice infected with MRSA.

295 unct antivirulence therapy for patients with MRSA infections.

296 In conclusion, the Xpert MRSA NxG assay is a sensitive and specific assay for the

297 The Xpert MRSA NxG assay recently received FDA clearance for the d

298 cal performance characteristics of the Xpert MRSA NxG assay with prospectively collected rayon nasal

299 .434-5.971) and initial DFU culture yielding MRSA (2.030; 1.452-2.838) predicted DFU-ISIs and that DF

300 Patients with initial DFU cultures yielding MRSA and protracted open ulcers had a high 24-month cumu